logo
The Best Time to Take Vitamin D for Maximum Absorption, According to Health Experts

The Best Time to Take Vitamin D for Maximum Absorption, According to Health Experts

Yahoo2 days ago

Reviewed by Dietitian Sarah Pflugradt, Ph.D., RDN, CSCSIt can be challenging to meet your vitamin D needs through diet alone.
It doesn't matter whether you take vitamin D in the morning or evening.
Take vitamin D with a meal or snack containing fat to enhance absorption.When it comes to the supplement aisle, multivitamins, omega-3s and probiotics might score the most real estate on the shelf. However, if that multi doesn't come with a dose of vitamin D, your doctor might recommend adding another pill to your routine. Known as the "sunshine vitamin," vitamin D is something most of us aren't getting enough of, and if you're wondering what time of day you should take it, we're here with the answer.
Roxana Ehsani, M.S., RD, CSSD, explains that vitamin D is one of four fat-soluble vitamins (A, E and K are the others). Our bodies make vitamin D after being exposed to the sun, and we can also get it through our diet. It plays 'many important roles in our body,' adds Ehsani. These include supporting your immune system, muscle and nerve function, your body's ability to absorb calcium and more.
Even though vitamin D is critical for overall health, research suggests that an estimated 25% of Americans are deficient in it. This could be because there are few food sources of vitamin D, and many people don't see sunshine during winter, live in regions with limited sunlight, and/or keep their skin covered while al fresco.
The average older adult's recommended Daily Value of vitamin D is 20 micrograms, which is equal to 800 international units (IU). For reference, one egg and a 3-ounce can of tuna each have above 1 mcg, 3 ounces of sockeye salmon delivers around 12 mcg, and 3 ounces of trout offers around 14 mcg. Unless you're taking a spoonful of cod liver oil (34 mcg) or eating salmon or trout daily, it can be challenging to meet that mark through food alone, since most food sources of vitamin D offer small amounts.
In the U.S., people get most of their dietary vitamin D from fortified milk, which contains around 100 IU per 8-ounce serving. But you'd need to drink a quart or more of milk daily to reach the DV—and milk consumption has been declining in recent years, a factor that some experts cite when discussing increased vitamin D deficiency.
That's why many people take a vitamin D supplement. However, you want to make sure not only that you're taking the right amount but also that your body is absorbing it properly. Read along to learn when to take your vitamin D supplement and what factors you should consider.
We'll cut to the chase: According to the current scientific consensus, our experts agree that it doesn't matter what time of the day you take your vitamin D supplement.
Many people find it handy to take supplements in the morning before the day sweeps them away. Others like to store them in a drawer near the kitchen cleaning supplies to pop after tidying up after dinner. It shouldn't make a substantial difference in absorption rates whether you swing to one side or the other, although it's easiest to remember if you pick one time and stick with it.
There are many factors to consider when taking any supplement, not just a vitamin D supplement; here's what you should keep in mind.
First, several conditions can influence an individual's vitamin D levels (or needs). These include osteoporosis or osteopenia, depression, kidney or liver disease and having a family history of neurological conditions, to name a few.
According to David Davidson, M.D., it's especially important for 'people with absorption issues, like inflammatory bowel disease or post-gastric bypass surgery' to work with their doctors to dial in their dose and receive personalized guidance about when to take vitamin D.
Body size can also alter absorbency and dosing, so be sure to ask your doctor for an individual recommendation before you set off to shop for supplements.
If you notice any nausea, constipation, noticeable appetite shifts or other adverse symptoms after taking your supplement, be sure to chat with your doctor.
Regardless of why you're including a vitamin D supplement in your regimen, it's important to consider your routine. It's difficult to reap the health benefits of vitamin D if you forget to take it most of the time.
Many people do well with 'habit stacking' or pairing the routine of taking vitamin D with something else they do daily on autopilot. Keep this in mind as you consider when to take your supplements. Ehsani shows how to put this into practice: 'If you always brush your teeth in the morning after breakfast, for instance, can you place your vitamin D supplements next to your toothbrush to remind you to take it each day?'
As with any new medication or supplement, it's important to check with a health care professional to determine the best time for you. As a general rule, though, 'the 'best' time is what works best for you,' Ehsani says.
'The timing of when to take the vitamin D supplement shouldn't matter, but it should be taken with food,' Davidson says. 'Because it's a fat-soluble vitamin, food, specifically healthy fats, will help with the absorption of vitamin D.'
For example, if you tend to have almond-butter toast each morning, 'consider taking it with that meal, as almond butter contains healthy fats,' Ehsani advises. Or, if you like to serve dinner with a side salad topped with a handful of walnuts and drizzled with a vinaigrette, take your vitamin D before you sit down to dig in. You could also choose to take your vitamin D with a glass of whole milk or a yogurt drink—you'll get the addition of calcium from the dairy and the vitamin D will help your body absorb the calcium.
'It may be impractical for you to take it with meals if you eat a majority of your meals away from home and can't realistically carry the vitamin D supplement with you everywhere you go,' Ehsani acknowledges. So, if that's not a realistic proposition, tell a health care professional about your schedule and when you think it might better fit, and ask for their runner-up recommendation.
There are two types of vitamin D: D2 and D3. UV-grown plants, fungi and fortified foods deliver D2, while we get D3 from sunlight and animal-based ingredients. While both are important and beneficial, vitamin D3 is more bioavailable than vitamin D2. This means that your body uses vitamin D3 more efficiently, so you might need a higher dose of vitamin D2 to achieve the same effects as you might with a supplement that includes just D3.
Before starting any new supplement regimen, talk to a health care professional about the best form of vitamin D for you. And if you already take a vitamin D supplement, confirm with them that you're taking the right form.
Related: 7 Things You Should Look for When Buying a Supplement, According to Dietitians
The best time to take a vitamin D supplement is when it fits well into your day—and when you can remember to take it.
When choosing a vitamin D supplement, consider opting for vitamin D3 over D2 so your body can use it more efficiently. Additionally, Ehsani and Davidson confirm that, ideally, you should take your vitamin D supplement with a meal that contains fat to help with absorption. For instance, if you like to take vitamin D first thing in the morning, well before you typically eat breakfast, or prefer to pop your supplements just before bed, think about doing so with a handful of nuts or a spoonful of nut butter, Ehsani says. That way, you'll enjoy two wellness wins in one: better vitamin D absorption and all the health benefits of nuts.
Related: 5 Supplements You Shouldn't Be Taking, According to a Dietitian
Read the original article on EATINGWELL

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share
Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Forbes

time9 minutes ago

  • Forbes

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Amazon Pharmacy is rolling out new features in hopes of attracting more seniors covered by Medicare's drug benefit, a potentially lucrative market dominated by CVS Health and Walgreens. In an announcement Tuesday, Amazon said it is launching a new 'caregiver support feature' that allows its customers to have someone else manage medications on their behalf. Once the caregivers are verified through a secure invitation, 'caregivers can now manage medications for their loved ones,' the company said. In addition, customers with Medicare Part D drug coverage can now access PillPack, Amazon's online pharmacy that is designed to simplify medication management, particularly for multiple prescriptions via pre-sorted and labeled packets delivered directly to patients' doors. It's the latest effort by the online retail giant Amazon to invest in its pharmacy business, which Drug Channels Institute estimates generated 'less than $2 billion in 2024 revenue - just 0.3% of the total prescription dispensing market.' Amazon doesn't disclose how many prescriptions it fills or financial information regarding its pharmacy and healthcare businesses. Amazon, which purchased PillPack seven years ago this month for more than $750 million, has yet to disclose revenues for its Amazon Pharmacy business in the parent company's quarterly earnings statements. In contrast, CVS filled 435 million prescriptions in the first quarter for an increase of 4.3% from the year ago period while Walgreens filled more than 309 million prescription in its most recent quarter, up 3.4%. Combined, Walgreens and CVS generated more than $370 billion in prescription revenues last year, According to Dryg Channels. CVS and Walgreens have the largest share of the U.S. prescription market by most measures at a combined 40% while Amazon's share is less than 1%, according to some studies. Neither CVS nor Walgreens would disclose how many Medicare Part D prescriptions the companies fill. By adding features for seniors, Amazon Pharmacy is looking to tap a Medicare prescription market growing by thousands every day. More than 11,000 Americans are turning 65 every day. Amazon is also trying to find a niche with Americans who are caring for an elderly family member. More than 50 million people in the U.S. 'are taking care of an aging family member,' Amazon said citing data from AARP. The aging population, coupled by industry statistics showing up to one-third of Americans don't take their medications as directed or never fill them. 'These updates deliver what our customers have been asking for—simpler medication management for themselves and their loved ones,' Amazon Pharmacy vice president John Love said. 'Whether you're a caregiver juggling multiple prescriptions for an aging parent, or a customer who could benefit from the convenience of pre-sorted packets delivered reliably each month, we're removing barriers and making pharmacy work better for you.'

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Associated Press

time12 minutes ago

  • Associated Press

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

WASHINGTON, June 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health, a healthcare technology company that delivers the evidentiary standard for real-world data and analytics, contracted by the Company. Results showed approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs each year, according to 60 Degrees Pharmaceuticals. In contrast, current estimates published by the Centers for Disease Control and Prevention (CDC) show only 2,000 cases in 2020. Babesia infections last at least 12 months in 14 percent of patients and may relapse up to 27 months later, as documented in the scientific literature. Many physicians treating tick-borne infections speculate the true duration of infection may be much longer. The claims data indicated approximately 31 percent of babesiosis cases persist longer than 30 days, and that nearly half of those are associated with chronic fatigue lasting longer than six months. Fatigue is the last symptom of babesiosis to resolve in acute disease. Chronic fatigue during babesiosis has not been systematically described in the literature. Further, the claims data, which captured approximately 40 percent of U.S. diagnostic data, showed that over three years, more than 12 million U.S. adults experienced chronic fatigue greater than six months in duration. Current Infectious Diseases Society of America advice and other professional guidelines do not mandate babesiosis as a differential diagnosis if a patient self-reports experiencing such fatigue. The Company is testing, through its clinical development program, the medical hypothesis that the true burden of babesiosis is much larger than claims data suggest and is a function of the incidence of chronic fatigue lasting six months or longer, multiplied by the proportion of such individuals with confirmable infections. A molecular incidence study in patients with chronic fatigue commissioned by the Company was recently completed. Once published, the data will allow establishment of a ceiling on the incidence of persistent babesiosis. Clinical Babesiosis Studies Sponsored by 60 Degrees Pharmaceuticals Three 60 Degrees Pharmaceuticals-sponsored clinical trials ( NCT06478641, NCT06207370, NCT06656351 ) are underway or planned to evaluate tafenoquine's safety and efficacy in treating humans diagnosed with babesiosis. Data are expected from one or more of these studies in the first half of 2026 and will be used as part of a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration for babesiosis, anticipated in 2026. About ARAKODA® (tafenoquine) Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based Pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the safeharbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store